Glyxambi commercialise en france?

See the DrugPatentWatch profile for Glyxambi

Is Glyxambi marketed in France, and who sells it?

Glyxambi is commercialized in France as a prescription medicine. It is sold under the brand name Glyxambi (active ingredients empagliflozin + linagliptin). [1]

What is Glyxambi used for in France?

Glyxambi is used in adults with type 2 diabetes to improve blood sugar control, typically as an add-on when diet and exercise and other treatments are not enough. [1]

Is Glyxambi available for all patients in France (reimbursement, access, prescribing)?

In France, access depends on being prescribed by a healthcare professional and on the product being included in the relevant prescribing/reimbursement framework used by French health authorities and insurers. Product availability and reimbursement details can vary over time by indication and local rules. [1]

What should patients check with their pharmacist or doctor?

Patients in France should confirm the exact presentation, dosage, and whether it matches their treatment plan, since Glyxambi is a fixed-dose combination and must be appropriate to the clinician’s selected doses. They should also ask about eligibility with their kidney function and other diabetes medicines. [1]

Sources

[1] https://www.ema.europa.eu/en/medicines/human/EPAR/glyxambi